FATE THERAPEUTICS INC (FATE) Operating Margin
- Operating margin · 12 months: Value -2058.08%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -2058.08% | Operating income / revenue. Period ending 2026-06-30. $-133.59M ÷ $6.49M × 100 ≈ -2058.08% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -133.59M USD | Operating Income (Loss) |
| Revenue | 6.49M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 100.35M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-133.59M | $6.49M | (m) | $100.35M | (m) | -2058.08% |
| 2026-03-31 | $-139.42M | $6.32M | (m) | $103.40M | (m) | -2207.47% |
| 2025-12-31 | $-147.70M | $6.65M | (m) | $107.83M | (m) | -2222.45% |
| 2025-09-30 | $-174.73M | $7.14M | (m) | $116.01M | (m) | -2448.24% |
| 2025-06-30 | $-192.37M | $8.47M | (m) | $124.83M | (m) | -2271.23% |
| 2025-03-31 | $-200.49M | $13.34M | (m) | $132.00M | (m) | -1503.47% |
| 2024-12-31 | $-210.28M | $13.63M | (m) | $135.00M | (m) | -1542.63% |
| 2024-09-30 | $-196.60M | $13.45M | (m) | $133.21M | (m) | -1462.06% |
| 2024-06-30 | $-195.50M | $12.32M | (m) | $132.83M | (m) | -1587.28% |
| 2024-03-31 | $-212.99M | $6.48M | (m) | $139.10M | (m) | -3287.85% |
| 2023-12-31 | $-190.51M | $63.53M | (m) | $172.60M | (m) | -299.86% |
| 2023-09-30 | $-206.85M | $106.21M | (m) | $227.97M | (m) | -194.75% |
| 2023-06-30 | $-241.97M | $119.25M | (m) | $273.51M | (m) | -202.91% |
| 2023-03-31 | $-262.51M | $136.87M | (m) | $313.94M | (m) | -191.80% |
| 2022-12-31 | $-308.39M | $96.30M | (m) | $320.45M | (m) | -320.23% |
| 2022-09-30 | $-313.35M | $69.01M | (m) | $302.78M | (m) | -454.04% |
| 2022-06-30 | $-281.58M | $68.26M | (m) | $276.09M | (m) | -412.53% |
| 2022-03-31 | $-245.25M | $63.12M | (m) | $242.81M | (m) | -388.56% |
| 2021-12-31 | $-216.99M | $55.85M | (m) | $215.52M | (m) | -388.56% |
| 2021-09-30 | $-181.01M | $54.67M | (m) | $184.99M | (m) | -331.08% |
| 2021-06-30 | $-157.88M | $48.01M | (m) | $162.55M | (m) | -328.87% |
| 2021-03-31 | $-139.80M | $40.06M | (m) | $141.20M | (m) | -348.98% |
| 2020-12-31 | $-128.09M | $31.43M | (m) | $125.62M | (m) | -407.47% |
| 2020-09-30 | $-123.76M | $18.34M | (m) | $111.85M | (m) | -674.83% |
| 2020-06-30 | $-119.40M | $13.21M | (m) | $104.36M | (m) | -903.76% |
| 2020-03-31 | $-114.77M | $10.56M | (m) | $99.32M | (m) | -1086.56% |
| 2019-12-31 | $-100.73M | $10.68M | (m) | $87.77M | (m) | -943.14% |
| 2019-09-30 | $-88.39M | $9.54M | (m) | $76.66M | (m) | -926.62% |
| 2019-06-30 | $-77.96M | $8.14M | (m) | $67.09M | (m) | -958.25% |
| 2019-03-31 | $-73.48M | $6.35M | (m) | $62.28M | (m) | -1157.96% |
| 2018-12-31 | $-67.09M | $4.74M | (m) | $56.02M | (m) | -1415.44% |
| 2018-09-30 | $-62.59M | (m) | (m) | $51.82M | (m) | (m) |
| 2018-06-30 | $-56.24M | (m) | (m) | $46.76M | (m) | (m) |
| 2018-03-31 | $-46.21M | (m) | (m) | $37.87M | (m) | (m) |
| 2017-12-31 | $-42.13M | $4.11M | (m) | $34.36M | (m) | -1025.94% |
| 2017-09-30 | $-37.53M | (m) | (m) | $30.70M | (m) | (m) |
| 2017-06-30 | $-35.58M | (m) | (m) | $28.93M | (m) | (m) |
| 2017-03-31 | $-34.02M | (m) | (m) | $27.78M | (m) | (m) |
| 2016-12-31 | $-31.96M | $4.40M | (m) | $26.45M | (m) | -726.10% |
| 2016-09-30 | $-31.22M | (m) | (m) | $25.66M | (m) | (m) |
| 2016-06-30 | $-29.16M | (m) | (m) | $23.85M | (m) | (m) |
| 2016-03-31 | $-28.37M | (m) | (m) | $21.93M | (m) | (m) |
| 2015-12-31 | $-27.78M | $2.43M | (m) | $19.86M | (m) | -1142.82% |
| 2015-09-30 | $-26.81M | (m) | (m) | $18.29M | (m) | (m) |
| 2015-06-30 | $-26.47M | (m) | (m) | $17.37M | (m) | (m) |
| 2015-03-31 | $-25.29M | (m) | (m) | $16.48M | (m) | (m) |
| 2014-12-31 | $-24.90M | (m) | (m) | $16.43M | (m) | (m) |
| 2014-09-30 | $-23.86M | (m) | (m) | $15.60M | (m) | (m) |
| 2014-06-30 | $-23.03M | (m) | (m) | $14.90M | (m) | (m) |
| 2014-03-31 | $-21.26M | (m) | (m) | $14.00M | (m) | (m) |
| 2013-12-31 | $-17.68M | $971.00K | (m) | $12.01M | (m) | -1820.29% |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $1.93M | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $2.72M | (m) | (m) | (m) | (m) |
| 2012-12-31 | $-13.56M | $2.67M | (m) | $12.00M | (m) | -507.75% |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $-13.29M | $1.17M | (m) | $9.86M | (m) | -1136.15% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |